Commodity price cyclicality — phosphate/potash prices and input costs (sulfur) drive the whole P&L, and management just curtailed production
One-line thesis. Mosaic is a cheap, well-financed, but deeply cyclical phosphate-and-potash miner trading below book value at a cyclical earnings trough — the balance sheet and the 4.2% dividend limit the downside, but there is no secular growth engine here, earnings are hostage to fertilizer prices and sulfur costs, and 2026 is shaping up as a down year (Q1'26 posted a net loss and management withdrew phosphate guidance). This is a Watch — a value/cyclical name to own only if you want the exposure, not a Synthos compounder.
◆ Synthos call — HoldMOS is a solid business largely reflected at ~$22 — fine to keep, no reason to chase; it gets interesting again below ~$19.
Downside Risk (lower = safer)
6/10 · High
Cheap on book (0.57×) & low net-debt/EBITDA 0.38×, but brutal commodity cyclicality — TTM EPS swung from $10 (2022) to a Q1'26 loss.
Growth Quality
3/10 · Low
No secular growth — a price-taker in phosphate/potash; forward EPS is a cyclical rebound off a trough, not a durable CAGR.
Exponential Potential
2/10 · Low
Zero exponential character — mature miner, ~$12B revenue for a decade, no acceleration, no room-to-run TAM story.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ -2%/yrTo justify today’s $21, earnings would have to compound roughly -2% a year for 10 years (9% discount rate). Analysts forecast ~17%/yr, so the market is pricing in LESS than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Mosaic digs up and sells two of the three main ingredients in farm fertilizer: phosphate and potash (plus a big business in Brazil). Farmers and fertilizer blenders all over the world buy it. Mosaic doesn't set the price — the price is set by global commodity markets, the same way a corn or oil producer takes whatever the market pays. So when fertilizer prices are high, Mosaic mints money (it earned over $10 a share in 2022); when they're low, profits collapse (it just posted a loss in early 2026).
Is the stock cheap or expensive? On the surface, cheap — you can buy the whole company for less than the accounting value of its mines and plants (below "book value"), and it pays a solid ~4.2% dividend. But cheap-looking cyclical stocks can stay cheap for years, because the low price is the market saying "earnings are about to fall." Right now earnings are falling.
Our verdict is Watch — not a buy, not a sell. It's financially sturdy and not expensive, but there's no growth story to power the stock higher, and the near-term earnings picture is weak.
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (a bit above average). The company won't go broke — low debt, real assets, a dividend — but the stock swings hard with commodity prices and just fell 43% in a year.
Growth Quality 3/10 (poor). This isn't a growing business; it's a mature miner whose sales have been flat for a decade and whose profits go up and down with prices it can't control.
Exponential Potential 2/10 (very low). No chance of the kind of fast, compounding growth Synthos hunts for — it's a slow, cyclical commodity company.
The one big worry: Mosaic's whole income depends on fertilizer prices and the cost of a raw material called sulfur. Sulfur prices recently spiked to records, squeezing margins so hard that management started shutting down (curtailing) some phosphate production. Until prices turn, earnings stay under pressure.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = MOS · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$21.13
Market cap$7B
P/E trailing1×
P/E FY26E / FY27E26× / 11×
EV / Sales0.6×
EV / EBITDA3.2×
Gross margin13.9%
Net margin6.0%
Dividend yield4.16%
Beta0.808
52-wk range$20 – $38
RSI(14)50
50 / 200-DMA$22 / $26
12-mo return+-43% (SPY +21%)
Street target$27 ($22–$35)
Analyst grades16 Buy · 26 Hold · 7 Sell
FMP ratingA-
Next earnings2026-08-05
What the experts actually said 0 traceable claims on MOS · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
The Mosaic Company (NYSE: MOS) is a Tampa-based global producer of concentrated phosphate and potash crop nutrients — the "P" and "K" of N-P-K fertilizer. It mines its own raw materials and processes them into products like DAP, MAP, and MOP (muriate of potash), plus animal-feed ingredients and a large Brazilian distribution/production business. It is a price-taker in a global commodity market: it does not set fertilizer prices, and its profitability is driven by the spread between realized selling prices and input/production costs (notably sulfur and ammonia for phosphate, and mining costs for potash). Founded/incorporated 2004, ~13,800 employees, CEO Bruce Bodine. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
By segment: Mosaic Fertilizantes (Brazil) $4.85B (40%) · Phosphates $4.58B (38%) · Potash $2.66B (22%). The Brazil segment is now the largest single piece — that's a distribution/production business tied to Brazilian ag demand and FX, and it's where Q1'26 pain concentrated (a $422M operating loss driven by the idling of Araxá/Patrocínio, per management).
By geography: FMP's geographic segmentation is not broken out for recent years (it reports a single "Total Geography" line for FY20–FY23). What the filings make clear is that the business is genuinely global, with a heavy Brazil/Latin America and North America footprint.
How it makes money, honestly: three commodity segments, each a spread business. When phosphate/potash prices rise faster than input costs, margins expand violently (2021–2022); when input costs (sulfur) spike or prices fall, margins compress or go negative (Q1'26 phosphate gross margin was $2/tonne, down from $111 a year earlier — see §9).
2. The expert thesis — no expert coverage
There is no expert coverage of Mosaic in the Synthos knowledge base.total_claims = 0; there are zero net-bullish (or bearish) voices, and therefore no claim_id values to cite. This is not an oversight to paper over — it is the honest state of the KB, and it is common for a mature Basic-Materials cyclical to sit outside the high-signal, forward-innovation voices Synthos tracks.
What that means for this note: the verdict is fundamentals- and quant-driven only. Every judgment below is anchored to the FMP financials, the analyst-estimate set, the technicals block, and management's own earnings release — not to any distilled expert conviction. Where a normal Synthos note would lean on a breadth-weighted panel, this one deliberately leans on nothing it cannot show you in the numbers. Treat the conviction rating as Low accordingly.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Moderate-High
Balance sheet is a genuine cushion — net-debt/EBITDA 0.38×, trades at 0.57× book, beta 0.808, 4.2% dividend. But this is a deeply cyclical price-taker: TTM adjusted EPS has swung from $10.06 (2022) to a Q1'26 net loss, max drawdown from peak −73%, and 2026 is a trough. The cheapness caps ultimate downside; the cyclicality raises near-term risk.
Growth Quality
3 · Low
No secular growth. Revenue has hovered ~$12B for a decade (FY20 $8.7B → FY22 $19.1B spike → FY25 $12.1B). ROE 5.9% TTM, ROIC 1.4% TTM — sub-cost-of-capital at the trough. Forward EPS "growth" is a cyclical rebound off a depressed base, not durable compounding. No moat that produces pricing power (price-taker).
Exponential Potential
2 · Very Low
Zero exponential character. A mature miner with no acceleration (2nd derivative of revenue is cyclical noise, not a trend) and no room-to-run TAM story — the fertilizer market grows with global crop acreage, low-single-digit. A $6.7B cap in a mature commodity does not multibag on fundamentals.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. For a cyclical, we anchor valuation on mid-cycle EBITDA / normalized EPS, not the trough print.
Case
Key assumptions
Fair value
Bull
Fertilizer up-cycle: phosphate/potash prices firm, sulfur normalizes, Brazil recovers. Normalized EPS re-rates toward ~$2.30 (FY29–30E) and the market pays a mid-cycle ~13–15× as earnings visibly recover. EV/EBITDA re-rates toward ~5×.
~$34 (+61%)
Base(our anchor)
Cyclical recovery is gradual: FY27E EPS ~$1.87 (Street), FY28E ~$2.02; a cyclical commodity miner earns a ~11–12× on recovering-but-modest earnings. Balance sheet + dividend support the floor.
~$22 (+4%)
Bear
Down-cycle persists: sulfur/input costs stay elevated, fertilizer prices soften, Brazil stays weak. FY26 EPS lands near the low (~$0.46) and FCF stays negative; the stock trades toward ~0.4× book.
~$13 (−38%)
Synthos fair value = the base case, ~$22 (+4%), with the full $13–$34 span as the honest range — a wide range, which is the correct picture for a commodity cyclical. This anchor sits below the Street's $27.36 consensus: we think the Street is anchoring on a mid-cycle earnings recovery that Q1'26 (a loss, withdrawn phosphate guidance, production curtailments) makes look optimistic near-term. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MOS is neither — it is a mature cyclical:
Forward growth is cyclical, not secular. Analyst estimates show revenue roughly flat-to-modestly-higher ($12.0B FY25 → ~$12.6B FY26E → ~$13.1B FY29E → ~$11.6B FY30E) — i.e. no trend, just cycle. EPS estimates ($0.82 FY26E → $1.87 FY27E → $2.02 FY28E → $2.33 FY29E → $2.23 FY30E) describe a recovery off a trough, then a plateau — the hallmark of a price-taker, not a compounder.
Acceleration (2nd derivative): there is no durable acceleration to point to. Revenue spiked +55% in 2022 on the Ukraine-war fertilizer shock, then fell −28% (2023), −19% (2024), then +8% (2025). This is cyclical noise, not exponential lift-off.
Room to run: the total addressable market (global crop nutrients) grows with planted acreage and yield intensity — low-single-digit long term. There is no TAM-expansion optionality (no new product category, no platform).
Reinvestment: heavy, mandatory maintenance capex (~$1.25B/yr guided for 2026) just to sustain the asset base — and FCF is currently negative (FY25 FCF −$535M; TTM FCF yield −7.3%). Reinvestment here is sustaining, not compounding.
Exponential Potential: Very Low (2/10). Own MOS, if at all, for cheap cyclical exposure and a dividend — never for exponential upside. This honest framing is why MOS sits in a satellite/cyclical bucket, not the Synthos core or degen sleeves.
Revenue: FY25 $12.05B, +8.4% off FY24 $11.12B — but that follows FY23 $13.70B (−28% that year) and the FY22 peak of $19.13B. The through-cycle picture: a ~$12B business that spikes in fertilizer up-cycles.
Quarterly trajectory (the trough is now): Q1'25 $2.62B → Q2 $3.01B → Q3 $3.45B → Q4 $2.60B → Q1'26 $3.00B, but the P&L turned red: Q1'26 net loss −$257.6M, EPS −$0.81 (adjusted EPS +$0.05), driven by $323M of pre-tax notable items and the idling of Araxá/Patrocínio in Brazil.
Margins (thin and cyclical): gross 13.9% TTM, EBITDA 19.9% TTM, operating 3.7% TTM, net 6.0% TTM. At the 2022 peak, gross margin was ~30%. This is a low-margin, capital-heavy processor.
Earnings: FY25 net income $540.7M, EPS $1.70 (up from FY24's $174.9M / $0.55, but far below FY22's $3.58B / $10.17). TTM net income per share metric ~$2.29 (the FY25 P/E of 9× reflects that TTM figure).
Cash flow (the red flag): FY25 operating CF $824.8M but capex −$1.36B → FCF −$534.6M. FCF has been negative through the capex-heavy trough; the dividend (~$280M/yr) and buybacks are currently funded partly by the balance sheet, not by free cash.
Balance sheet (the cushion): net debt $5.0B, net-debt/EBITDA 0.38× TTM, total debt/equity 0.10×, current ratio 1.25×. Equity $12.08B vs $6.7B market cap → P/B 0.57×. The company is investment-grade and in no financial distress; the balance sheet is the reason downside is bounded.
6. Valuation — priced in or room?
MOS is a two-faced valuation. On trailing/asset metrics it looks cheap: 9× trailing EPS, 0.57× book, EV/EBITDA 3.2×, EV/Sales 0.63×, FCF-adjusted it's cheaper than peers on assets. FMP's quant rating is A- on that basis. But on forward earnings it is not cheap: FY26E EPS is only $0.82 (trough), putting the forward P/E at ~26× — because the "E" collapses in a down-cycle. That is the cyclical valuation trap: the trailing multiple looks low precisely when earnings are about to fall, and looks high when earnings are depressed.
The honest way to value a price-taker is on normalized / mid-cycle earnings. On the Street's own out-year estimates (FY28–29E EPS ~$2.0–2.3), a mid-cycle ~11–12× gets you to the low-$20s — our ~$22 base. A genuine fertilizer up-cycle (bull) supports the low-$30s; a persistent down-cycle (bear) takes it toward book-discount low-teens. Street targets (context): consensus $27.36, high $35, low $22, with a Hold consensus (16 Buy / 26 Hold / 7 Sell). Our base is below consensus because Q1'26 (loss, withdrawn phosphate guidance, curtailments) makes the near-term recovery look slower than the Street's targets imply. Not a value trap to short, not a bargain to back up the truck — a fairly-valued cyclical near mid-cycle.
7. Technicals (from the tech block)
Trend: down. $21.13 sits below the 50-DMA ($22.47) and the 200-DMA ($26.26), and the 50 is below the 200 (death-cross posture). MACD −0.34 (negative).
Location:−44% off the 52-week high ($37.81), only +6.6% off the 52-week low ($19.82) — pinned near the lows. Max drawdown from peak −73% captures how violent the cyclical de-rate has been.
Momentum: RSI(14) 50 — neutral, neither oversold nor overbought. No mean-reversion signal either way.
Relative strength (the tell): MOS −42.6% 12-mo vs SPY +20.6% and QQQ +30.3%; −20.4% 3-mo vs SPY +13.7%. Persistent, heavy underperformance of both the market and the Nasdaq — the tape is voting on the down-cycle.
Read: technicals confirm the fundamental caution — a downtrend near 52-week lows with no momentum turn yet. There is no technical reason to rush in; a value-cyclical buyer would want either a commodity-price turn or a base to form near the lows before adding.
8. Moat & competitive position
Mosaic's "moat" is narrow and asset-based, not pricing-based. It has scale, integrated mine-to-market assets, and low-cost potash reserves (Esterhazy in Canada, Brazilian phosphate) — real barriers to entry (you can't quickly build a phosphate mine), but no pricing power, because it sells undifferentiated commodities into a global market set by supply/demand and by low-cost sovereign producers (Morocco's OCP in phosphate, Nutrien/Belarus/Russia in potash). Cost position, not brand or switching costs, is the whole game. When it's a low-cost producer in a given commodity it earns through the cycle; when input costs (sulfur) spike, even that erodes — which is exactly what forced the Q1'26 curtailments.
Peer set (FMP-supplied, market cap): Note the FMP peer list is a generic Basic-Materials basket rather than pure fertilizer comps — Alcoa $12.8B, Eastman Chemical $7.9B, Equinox Gold $8.0B, Gerdau $8.1B, Hecla Mining $11.0B, Iamgold $9.6B, ICL Group $6.5B (the one true fertilizer peer here), NewMarket $7.2B, Ternium $8.2B, Westlake $9.6B. The more relevant true comps (not in this list) are Nutrien, CF Industries, and OCP — MOS is a mid-cap pure-play on phosphate/potash within that group, more phosphate-weighted (and thus more sulfur-cost-exposed) than Nutrien.
9. Management, capital allocation & guidance
Capital allocation: in a down-cycle, management is doing the textbook-defensive things — cutting 2026 capex to $1.25B (deferring less-time-sensitive projects), a $50M annualized cost-savings initiative (on top of a prior $100M value-capture effort), divesting the Carlsbad potash mine (closed April 2026), pursuing strategic alternatives for Araxá/Patrocínio in Brazil, and monetizing Florida real estate (+$31M). The regular dividend was maintained at $0.22/quarter ($0.88/yr, ~4.2% yield). Honest flag: with FCF negative at the trough, the dividend is currently supported by the balance sheet, not by free cash — sustainable given low leverage, but worth watching if the down-cycle persists.
Insider activity: the recent Form 4s (filed 2026-06-01) are routine director equity awards and RSU conversions (price $0, A-Award / M-Exempt) — annual board compensation mechanics, not open-market buying or selling. No signal either way.
Management's own guidance (half-weighted — their own self-interested words). Per the SEC 8-K earnings release for Q1'26 (filed 2026-05-11), management's own forward statements: (a) 2026 capex now $1.25B (down, deferrals); (b) phosphate production guidance for 2026 has been withdrawn amid record sulfur prices and raw-material constraints, with partial curtailments at Louisiana and Bartow plus scaled-back Brazil production, though management says it does not expect material impact to medium-term operating rates; (c) potash production still expected at ~9 million tonnes in 2026 (Esterhazy strength offsetting the Carlsbad divestiture); (d) Q2'26 potash guidance: sales volumes 1.9–2.1M tonnes at realized mine-gate MOP prices $260–$280/tonne. Treat all of this as management's self-interested framing (half-weight): the tell is that a company withdrawing guidance and curtailing production is signaling a genuinely difficult near-term market — which supports our cautious base case.
10. Catalysts & what to watch
Next earnings: 2026-08-04 (Q2'26; Street EPS $0.16, revenue ~$3.05B). The key lines: phosphate margin/tonne recovery (Q1 was $2/tonne — does it bounce?), sulfur cost trajectory, and whether phosphate production guidance gets reinstated.
Fertilizer prices: realized MOP (potash) and DAP (phosphate) prices vs input costs — the single biggest swing factor for the whole thesis.
Sulfur costs: management explicitly flagged record sulfur prices as the trigger for curtailments; sulfur normalizing is the near-term margin catalyst.
Brazil (Mosaic Fertilizantes): recovery from the Q1 loss and resolution of the Araxá/Patrocínio strategic alternatives (potential Araxá sale, niobium optionality at Patrocínio).
FCF inflection: capex rolling off and FCF turning positive would confirm the balance-sheet cushion isn't being drawn down.
Thesis tripwires (what would change the call): a sustained fertilizer up-cycle with expanding phosphate margins (→ upgrade toward Buy — Tactical); OR a persistent down-cycle that pressures the dividend and pushes FCF materially negative for multiple quarters (→ downgrade toward Avoid).
11. Key risks
Commodity cyclicality (structural, dominant): MOS is a price-taker; phosphate/potash prices and input costs (sulfur, ammonia, energy) drive the entire P&L. Earnings have ranged from $10+/share to a quarterly loss within four years.
Input-cost squeeze (live): record sulfur prices forced Q1'26 phosphate curtailments and a withdrawn production guide — an ongoing, unresolved margin risk.
Brazil concentration: Mosaic Fertilizantes is now the largest segment and the source of the Q1'26 operating loss; Brazilian FX, ag demand, and the Araxá/Patrocínio wind-down add volatility.
Negative FCF at the trough: FY25 FCF was −$535M; the dividend is currently balance-sheet-supported. Low leverage makes this manageable, not free.
No secular growth / value-trap risk: a cheap-on-book cyclical can stay cheap for years if the up-cycle doesn't arrive.
No expert corroboration: unlike Synthos conviction names, there is zero KB coverage here — the thesis rests entirely on quant/fundamentals with no independent expert cross-check.
12. Verdict, position sizing & monitoring
Watch. Mosaic is a financially sturdy, cheap-on-assets, deeply cyclical fertilizer miner at (or near) a cyclical earnings trough. The balance sheet (net-debt/EBITDA 0.38×, 0.57× book) and the ~4.2% dividend bound the downside, but there is no secular growth engine, forward earnings are a cyclical rebound rather than durable compounding, near-term conditions are weak (Q1'26 loss, withdrawn phosphate guidance, curtailments), and the tape confirms it (−43% 12-mo, downtrend). Our base-case fair value of ~$22 (+4%) sits essentially at today's price — the market is pricing this roughly fairly for a mid-cycle commodity name. That combination — fair value, no growth, high cyclicality, zero expert conviction — is the definition of a Watch, not a Buy.
Sizing: if owned at all, satellite/cyclical only, ≤2%, and only by investors who specifically want commodity-fertilizer exposure and can stomach the swings. Not a core holding, not a Synthos flagship candidate.
What would move it to Buy — Tactical: a confirmed fertilizer up-cycle (firming phosphate/potash prices, normalizing sulfur, expanding margins) with the stock still near book — that's the cyclical's asymmetric setup.
Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $21.13.
Single biggest risk: commodity-price and input-cost cyclicality — the entire earnings stream is hostage to fertilizer prices and sulfur costs that management does not control.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of MOS in the Synthos knowledge base, so no claim_id is cited. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here that means the note is explicitly fundamentals/quant-only.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release filed 2026-05-11. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: the §9 guidance is management's own book, half-weighted by design — and notably includes a withdrawn phosphate guide, which we read as a cautionary tell.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").